News
CNBC on MSN18d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sureNovo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...
Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results